OraSure Technologies to Commemorate World AIDS Day by Ringing NASDAQ Opening Bell
27 November 2019 - 12:00AM
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight
against HIV, today announced its plans to commemorate World AIDS
Day.
On Monday, Dec. 2nd, OraSure will ring the opening bell for the
NASDAQ Stock Market. The bell ringing ceremony will be followed by
an expert panel discussion sponsored by The AIDS Institute focused
on the Administration’s initiative, "Ending the HIV Epidemic:
A Plan for America."
“If we want to make progress on the national goal to end the HIV
epidemic by 2030, we must change the narrative surrounding
infectious diseases,” said OraSure President and CEO, Stephen S.
Tang, Ph.D. “The theme of World AIDS Day 2019 is ‘Communities make
the difference.’ This battle is far too large for one group or one
company to take on alone. OraSure is proud to be a member of the
community of advocacy, support and care that is needed to end the
AIDS epidemic.”
The expert panel discussion, titled The Plan for
America: Applying Lessons Learned in the Global Fight Against
HIV/AIDS to the U.S., will explore strategies to end the HIV
epidemic in America by 2030. Moderated by Carl Schmid, Deputy
Executive Director, The AIDS Institute and Co-chair of the
Presidential Advisory Council on HIV/AIDS (PACHA), the panel will
include C. Virginia Fields, President and CEO, National Black
Leadership Commission on Health, Inc.; Nina Hasen, Ph.D., Vice
President HIV/TB, Population Services International; Jay Butler,
MD, Deputy Director for Infectious Diseases, CDC; and John Sapero,
Office Chief, HIV Prevention Program for the Arizona Department of
Health and PACHA member.
OraSure will also host a symposium on December 2nd in Rwanda
during the International Conference on AIDS and STIs in Africa. The
panel discussion will address the importance of HIV self-testing
and includes experts from throughout Africa.
In addition to these events in New York and Africa, OraSure
employees and customers will take part in global testing efforts on
World AIDS Day.
About OraSure Technologies HIV Tests
The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test is the first
FDA approved, CLIA-waived, rapid point-of care test that can detect
antibodies to both HIV-1 and HIV-2 with greater than 99 percent
accuracy in as little as 20 minutes, using an oral fluid,
finger-stick or venipuncture whole blood, or plasma sample.
The OraQuick® In-Home HIV Test is the first and only oral fluid
rapid over-the-counter (OTC) HIV test approved in the U.S. The
OraQuick® In-Home HIV Test can detect antibodies to both HIV-1 and
HIV-2 with an oral swab, providing a confidential in-home testing
option with results in as little as 20 minutes. It is the first
rapid diagnostic test for any infectious disease that has been
approved by the FDA for sale to the consumer market.
The OraQuick® HIV Self-Test (HIVST) is a rapid, point-of-care
test that allows an individual to detect antibodies to both HIV-1
and HIV-2 with a simple oral swab and provides a result in as
little as 20 minutes in the privacy of an individual’s home, at
outreach testing settings, in the pharmacy or at community based
screening events. Based on the same OraQuick® platform that is used
for the FDA-approved OraQuick® In-Home HIV Test and the WHO
Prequalified OraQuick® Rapid HIV-1/2 Antibody Test used by health
care professionals worldwide, the platform has been used to test
millions in international markets.
About OraSure Technologies
OraSure Technologies is empowering the global community to
improve health and wellness by providing access to accurate,
essential information. OraSure is a leader in the development,
manufacture, and distribution of point-of-care diagnostic tests,
molecular collection devices, and other technologies designed to
detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and Hepatitis C (HCV) on the
OraQuick® platform, sample self-collection and stabilization
products for molecular applications, and oral fluid laboratory
tests for detecting various drugs of abuse. Together with its
wholly-owned subsidiaries (DNA Genotek, CoreBiome, Diversigen and
Novosanis), OraSure provides its customers with value-added,
end-to-end solutions that encompass tools, diagnostics and
services. OraSure’s portfolio of products is sold globally to
various clinical laboratories, hospitals, clinics, community-based
organizations, and other public health organizations, research
institutions, distributors, government agencies, physicians’
offices, commercial, and industrial entities and consumers.
For more information on OraSure Technologies, please visit
www.orasure.com.
To cover the bell ringing or the expert panel discussion in New
York, please contact:
Amy Koch Manager, Corporate Communications 484-353-1577
media@orasure.com
Company contact:
Roberto
CucaChief Financial
Officer610-882-1820Investorinfo@orasure.comwww.orasure.com |
Jeanne MellVP
Corporate
Communications484-353-1575media@orasure.comwww.orasure.com |
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2023 to Jul 2024